Seelos Therapeutics, Inc. - Common Stock (SEEL)

Here are brief overviews of five Nasdaq stocks, tailored to highlight their strengths and receive public attention:

EQNX::TICKER_START (NYSECYBN),NASDAQ:CMPSNASDAQCMPS)(NASDAQ:MNMDNASDAQMNMD,(NASDAQ:SEELNASDAQ),(NASDAQ:ATAIATAI) EQNX::TICKER_END

Lucy Scientific Discovery (NASDAQLSDI) (“Lucy” or the “Company), a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses, just announced the acquisition of the Intellectual Property of High Times, its Licensing Agreements and Royalty Streams in all-stock transaction. This was a brilliant strategic business move.

Former CFO of Amgen and Walt Disney, Richard Nanula, is now Advancing Psychotropic Medicine

EQNX::TICKER_START (NYSECYBN),NEO:CYBN),NASDAQ:CMPSNASDAQCMPS)(NASDAQ:MNMDNASDAQMNMD,(NASDAQ:SEELNASDAQ),(OTCQX:NUMIF) EQNX::TICKER_END

The past two decades have been characterized by numerous drug reform initiatives that have resulted in controlled substances such as cannabis and psychedelics being recognized for their medical potential. While there has been a decent amount of research into cannabis thanks to loosening reforms across the country, psychedelic research is still in its infancy .

Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the general election ballot. Known as the Natural Medicine Health Act (NMHA), the proposal would legalize the cultivation, manufacturing, testing, transportation, sale and purchase of psilocybin […]

A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical study using the Company’s unique psychedelic molecule, BMND08. Biomind Labs is a biotech research and development company looking into new medicines and nanotech delivery systems […]

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical study using the Company’s unique psychedelic molecule, BMND08. Biomind […]

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever.  According to a National Institute of Health survey, the amount of people between age 19 to 30 who reported using one or the other are at the highest rates since the […]

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a number of mental health conditions. The Tesla CEO said in a tweet last month that he had interacted with many people who […]

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in magic mushrooms. Authorities plan to greenlight a particular species of magic mushroom for therapeutic use in the state starting in 2023. […]

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year, and despite the abundance of antianxiety medications available, treatment resistance occurs in roughly 30% of patients. Anxiety disorders have a significant […]

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – March 30, 2022 –  Depression and anxiety affect millions around the world and the venom of a toad is the latest  psychedelic compound being used as an alternative treatment. The Sonoran desert toad is the only animal on earth that produces 5-MeO-DMT, a […]

NetworkNewsWire Editorial Coverage: Global destigmatization, changing regulations and an upswing in research are speaking loudly to the opportunity for psychedelics to provide tangible improvements in medicine to address some of the most resistant, devastating and expensive conditions known to man. For decades, drugmakers have spent billions of dollars searching for therapies that can safely help people quit smoking and alleviate anxiety, as well as treat those with notoriously difficult diseases such as autism. Unfortunately, the conventional efforts have been to little avail. Fortunately, meaningful progress is being made with psychedelics across multiple fronts, such as the work of Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (Profile), a biopharmaceutical firm formed in 2020 for the purpose of developing innovative therapeutics to treat PTSD, addiction and other mental health disorders. Mydecine is part of a renaissance for psychedelic medicine research that has captured investors’ attention, albeit through individual companies such as Mind Medicine (MindMed) Inc. (NASDAQMNMD) and Seelos Therapeutics Inc. NASDAQ: SEELNASDAQSEEL)

NetworkNewsWire Editorial Coverage: The fact that psychedelics is a nascent industry doesn’t seem to be discouraging savvy investors exploring the opportunities. A recent Fortune article noted that “despite being an industry in its early stages, the potential for psychedelic health care is growing, with the market projected to reach $10.75 billion by 2027. . . . Smart capital is moving in to take advantage of the opportunity to invest in the next frontier.” The multibillion-dollar potential combined with solid promise in psychedelic drug treatments, particularly in the hard-to-treat mental health sector, such as depression, addiction, post-traumatic stress disorder and anxiety, bodes well for pioneering psychedelic companies, including Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (Profile). Tryp is one of a handful of companies focused on psychedelics; others venturing forward in the space include Seelos Therapeutics Inc. (NASDAQSEEL), Field Trip Health Ltd. (TSX: FTRP) NASDAQ: FTRPNASDAQFTRP)

Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the medical cost of mental health conditions is estimated to rise to $6 trillion by 2030. The prevalence of mental health disorders has risen exponentially but […]

FN Media Group Presents Microsmallcap.com Market Commentary

FN Media Group Presents Microsmallcap.com Market Commentary

Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to see more demand and hence likely to attract major investments in the near future. The Psychedelic Drugs market is growing rapidly due […]

Palm Beach, FL –May 20, 2021 – Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to treat this condition. Pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S.  Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.  The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc.  Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Athenex, Inc. NASDAQ: ATNXNASDAQATNX)(NASDAQ: SEELNASDAQSEEL, Trillium Therapeutics Inc. (NASDAQ: TRILNASDAQ) (TSX: TRIL), Marker Therapeutics, Inc. (NASDAQ: MRKRMRKR).

FN Media Group Presents Microsmallcap.com Market Commentary